It will therefore be important to investigate whether ectopic overexpression of DTX3L xenograft tumors (alone or simultaneously in combination with ARTD9 and/or STAT1) may positively or negatively affect chemoresistance, enhanced growth and/or metastasis of HR-DLBCL tumors in vivo. The gene discussed is PARP9; the disease is diffuse large B-cell lymphoma.